Startseite The haptoglobin phenotype is associated with the Epstein-Barr virus antibody titer
Artikel
Lizenziert
Nicht lizenziert Erfordert eine Authentifizierung

The haptoglobin phenotype is associated with the Epstein-Barr virus antibody titer

  • Reinhart Speeckaert , Marijn M. Speeckaert , Elizaveta Padalko , Lutgarde R. Claeys und Joris R. Delanghe
Veröffentlicht/Copyright: 4. Juni 2009
Veröffentlichen auch Sie bei De Gruyter Brill

Abstract

Background: Epstein-Barr virus (EBV) is a human herpes virus that persists for life and is associated with several neoplasms. Haptoglobin (Hp), a polymorphic multifunctional plasma protein, exerts several immunomodulatory effects. The present study investigated the influence of the genetic polymorphism of Hp on EBV serology.

Methods: Patients without immunoglobulin G (IgG) titers of EBV were compared according to Hp phenotypes (Hp 1-1, Hp 2-1, Hp 2-2; determined by starch gel electrophoresis) in 208 individuals against 918 healthy subjects with unknown EBV status.

Results: The Hp 1-1 phenotype was associated with a lower EBV antibody titer (p=0.0005).

Conclusions: Our study confirms the involvement of the Hp phenotype in infection with EBV. Phenotypes with a higher Hp concentration (Hp 1-1 and Hp 2-1) are less prone to positive EBV serology.

Clin Chem Lab Med 2009;47:826–8.


Corresponding author: Prof. Dr. Joris R. Delanghe, Laboratory of Clinical Chemistry 2P8, Ghent University Hospital, De Pintelaan 185, 9000 Gent, Belgium Phone: +32 9 332 29 56, Fax: +32 9 332 49 85,

Received: 2009-3-18
Accepted: 2009-4-20
Published Online: 2009-06-04
Published in Print: 2009-07-01

©2009 by Walter de Gruyter Berlin New York

Artikel in diesem Heft

  1. Editorials
  2. Change through continuity
  3. EFCC and Labs are Vital announce an Award for Outcomes Research in Laboratory Medicine
  4. Review
  5. The prevalence and risk factors for gallstone disease
  6. Opinion Paper
  7. Measurement uncertainty of test kit results – the ELISA example
  8. Genetics and Molecular Diagnostics
  9. Expression of RhoA and RhoC in colorectal carcinoma and its relations with clinicopathological parameters
  10. High-sensitive microarray substrates specifically designed to improve sensitivity for the identification of fetal paternally inherited sequences in maternal plasma
  11. A new CYP21A2 nonsense mutation causing severe 21-hydroxylase deficiency
  12. The haptoglobin phenotype is associated with the Epstein-Barr virus antibody titer
  13. General Clinical Chemistry and Laboratory Medicine
  14. Evaluation of analytical performance of the Pathfast® cardiac troponin I
  15. Diagnostic performance of the ARCHITECT C-Peptide immunoassay
  16. Clinical significance of anti-cyclic citrullinated peptide antibodies in Egyptian patients with chronic hepatitis C virus genotype IV infection
  17. Cerebrospinal fluid and serum uric acid levels in patients with multiple sclerosis
  18. Therapeutic drug monitoring and drugs of abuse testing on the cobas® 6000 analyzer series: analytical performance under routine-like conditions
  19. Is serum γ-glutamyltransferase an exposure marker of xenobiotics? Empirical evidence with polycylic aromatic hydrocarbon
  20. Reference Values and Biological Variations
  21. Gender difference and determinants of C-reactive protein level in Korean adults
  22. Cancer Diagnostics
  23. Quantitative telomerase activity in circulating human leukocytes: utility of real-time telomeric repeats amplification protocol (RQ-TRAP) in a clinical/epidemiological setting
  24. Intrathecal synthesis of tumor markers is a highly sensitive test in the diagnosis of leptomeningeal metastasis from solid cancers
  25. Letters to the Editor
  26. Hyperleukocytosis: pseudohyperkalaemia and other biochemical abnormalities in hyperleukocytosis
  27. Review of the prevalence of macroprolactinaemia in a South African hospital
  28. A novel aberrant form of e13a2 BCR-ABL1 transcript in chronic myelogenous leukemia undetectable with the standardized real-time quantitative polymerase chain reaction from the Europe Against Cancer Program
  29. Positive correlations between serum and plasma matrix metalloproteinase (MMP)-2 or MMP-9 levels in disease conditions
  30. Doubt on prevention of false-positive results of cardiac troponin I by recentrifugation
  31. Plasmalogens as a marker of elevated systemic oxidative stress in Parkinson's disease
Heruntergeladen am 24.10.2025 von https://www.degruyterbrill.com/document/doi/10.1515/CCLM.2009.193/html
Button zum nach oben scrollen